Development of a Risk‐Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease
Hepatology Research · 2026-11 · 56 (11) · 1696-1702
DOI: 10.1111/hepr.70245 ↗Abstract
ABSTRACT Background and Aim Sarcopenia is associated with poor outcomes in patients with chronic liver disease (CLD), but current screening based on reduced muscle strength may fail to identify early skeletal muscle loss. This study aimed to develop a risk‐estimation model for identifying patients at risk of early skeletal muscle mass loss before patients meet the diagnostic criteria for overt sarcopenia. Methods This retrospective study included 1276 CLD patients who underwent handgrip strength testing and computed tomography‐based skeletal muscle index (SMI) assessment between 2015 and 2026. SMI ratio and grip ratio were defined as relative deviations from sex‐specific reference values established by the Japan Society of Hepatology. Early skeletal muscle mass loss was defined as an SMI ratio < 0.05. A multivariable logistic regression model incorporating grip ratio, age, sex, platelet count, albumin‐bilirubin score, creatinine, body mass index, hepatocellular carcinoma status, and the interaction between grip ratio and sex was developed (MYO‐SCAN score). Results The model demonstrated good discrimination for identifying patients with an SMI ratio < 0.05 with an area under the receiver operating characteristic curve (AUC) of 0.847. The optimal cutoff value was 0.435, yielding sensitivity and specificity of 0.777 and 0.764, respectively. Risk‐estimation performance was significantly superior to grip ratio alone (AUC 0.847 vs. 0.614, p < 0.001). Bootstrap validation showed minimal optimism with an optimism‐corrected AUC of 0.843. Conclusion The MYO‐SCAN score may facilitate early identification of CLD patients at risk of skeletal muscle mass loss, including those who may be overlooked by grip‐strength–based screening.
EUVIMED